Concepedia

Wesley Blackaby

WB

Statistics

Publications

20

Citations

2.1K

H-Index

15

Active since

2005

Affiliations

Charles River Laboratories (United Kingdom)(Current)

MSD (UK) Limited (United Kingdom)

CHDI Foundation

Mission Therapeutics (United Kingdom)

The Gurdon Institute

Wesley Blackaby is an author at Charles River Laboratories (United Kingdom) specializing in pharmacology, medicinal chemistry, and drug discovery.

ORCID

Publications per year

2005–2023

20

Publications

20

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia

Eliza Yankova, Wesley Blackaby, Mark R. Albertella et al. · Nature · 2021 · 1.3K citations · Full text

, , +13

Targeting the m<sup>6</sup>A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Hannah M. Burgess, Daniel P. Depledge, Letitia Thompson et al. · Genes & Development · 2021 · 144 citations · Full text

, , +16

Imidazo[1,2<i>-a</i>]pyrimidines as Functionally Selective and Orally Bioavailable GABA<sub>A</sub>α2/α3 Binding Site Agonists for the Treatment of Anxiety Disorders

Simon Goodacre, Leslie J. Street, David J. Hallett et al. · Journal of Medicinal Chemistry · 2005 · 132 citations · Full text

, , +17

Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity

Andrew A. Guirguis, Yaara Ofir-Rosenfeld, Kathy Knezevic et al. · Cancer Discovery · 2023 · 115 citations

, , +17

Evaluation of 5-(Trifluoromethyl)-1,2,4-oxadiazole-Based Class IIa HDAC Inhibitors for Huntington’s Disease

Andrew J. Stott, Michel Maillard, Vahri Beaumont et al. · ACS Medicinal Chemistry Letters · 2021 · 45 citations · Full text

, , +16

1–5 of 20